Factors affecting tumor 18F-FDG uptake in longitudinal mouse PET studies

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-11

  Sha, Wei ^a   Ye, Hu ^a   Iwamoto, Keisuke S ^a   Wong, Koon Pong ^a   Wilks, Moses Quinn ^a   Stout, David ^a   McBride, William ^a   Huang, Sung Cheng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

F FDG; Glucose; Kinetic; PET; Tumor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BLOOD LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; GLIOBLASTOMA; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 84881239644     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-51     Document Type: Article

References (27)

1. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W: Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006, 12(19):5659-5667.
2. 18 F-FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med 2009, 50(2):290-295.
3. Huang SC: Anatomy of SUV. Nucl Med Biol 2000, 27(7):643-646.
4. Adams MC, Turkington TG, Wilson JM, Wong TZ: A systematic review of the factors affecting accuracy of SUV measurements. Am J Roentgenol 2010, 195(2):310-320.
5. Krak NC, van der Hoeven JJM, Hoekstra OS, Twisk JWR, van der Wall E, Lammertsma AA: Measuring FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging 2003, 30(5):674-681.
6. 18F-FDG PET in classifying lymphomas. J Nucl Med 2005, 46(10):1659-1663.
7. Torizuka T, Clavo AC, Wahl RL: Effect of hyperglycemia on in vitro tumor uptake of tritiated FDG, thymidine. L-methionine and L-leucine. J Nucl Med 1997, 38(3):382-386.
8. Stahl A, Ott K, Schwaiger M, Weber WA: Comparison of different SUVbased methods for monitoring cytotoxic therapy with FDG PET. European J Nuclear Med Molecul Imagin 2004, 31(11):1471-1478.
9. Hadi M, Bacharach SL, Whatley M, Libutti SK, Straus SE, Rao VK, Wesley R, Carrasquillo JA: Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV. Nucl Med Biol 2008, 35(4):441-445.
10. 18]fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. Radiology 1997, 203:169-172.
11. 18 F-FDG in mice. J Nucl Med 2011, 52(5):800-807.
12. 18 F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data. J Nucl Med 2007, 48(12):2037-2045.
13. Barrett PHR, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM: SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 1998, 47(4):484-492.
14. Patlak CS, Blasberg RG, Fenstermacher J: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983, 3:1-7.
15. Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE: Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980, 238:E69-E82.
16. Spence AM, Muzi M, Graham MM, O'Sullivan F, Krohn KA, Link JM, Lewellen TK, Lewellen B, Freeman SD, Berger MS, Ojemann GA: Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11] glucose and FDG: analysis of the FDG lumped constant. J Nucl Med 1998, 39(3):440-448.
17. Lindstrom MJ, Bates DM: Nonlinear mixed effects models for repeated measures data. Biometrics 1990, 46:673-687.
18. Pinheiro J, Bates D, DebRoy S, Sarkar D, the R Development Core Team: nlme: linear and nonlinear mixed effects models. R package version 3. 2013:1-109.
19. 18 F-FDG PET studies in mice. J Nuclear Med 2006, 47(6):999-1006.
20. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN: FDGPET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998, 39(6):1030-1033.
21. Higashi K, Clavo AC, Wahl RL: In vitro assessment of 2-fluoro-2-deoxy-Dglucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993, 34(5):773-779.
22. 18 F]fluorothymidine positron emission tomography. J Clinic Oncol 2011, 29(13):1701-1708.
23. Soret M, Bacharach SL, Buvat I: Partial-volume effect in PET tumor imaging. J Nuclear Med 2007, 48(6):932-945.
24. Sha W, Iwamoto K, McBride W, Huang SC: Effects of glucose and free fatty acid levels on in vitro 18 F-FDG uptake in tumor cells. J Nucl Med 2011, 52:602.
25. Allen LA, Gerritsen ME: Regulation of hexose transport in cultured bovine retinal microvessel endothelium by insulin. Experiment Eye Res 1986, 43(4):679-686.
26. Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996, 98(4):894-898.
27. 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med 2005, 46:1531-1536.